Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Alcidion Group’s fair value estimate is set at A$0.14 and remains unchanged in the latest update, even as underlying model inputs have been fine tuned. That stability lines up with recent sector research, where analysts often adjust discount rates and growth assumptions while keeping a steady view on valuation when product roadmaps, guidance and cash generation frameworks look consistent. Read on to see what is driving this refreshed narrative and how you can track the key signposts from here.

Stay updated as the Fair Value for Alcidion Group shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Alcidion Group.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Wells Fargo took a more positive stance on Alcon, upgrading the stock to Overweight and setting a US$97 price target. The firm cited new product cycles like Unity and Tryptyr as supporting the company’s growth profile. Barclays lifted its Alcon price target to US$90 and highlighted "bright spots" in the portfolio following the Q4 report. The bank pointed to products that, in its view, support the company’s execution and medium term outlook. BTIG raised its Alcon target to US$92, pointing to solid Q4 results, a steady product cadence and profitability, and the company’s flexibility around M&A and buybacks given its free cash flow generation.

🐻 Bearish Takeaways

Stifel and Deutsche Bank both reduced their Alcon price targets in early May, signalling more cautious expectations around future returns even as they continue to cover the stock within the medical technology and supplies sector. BTIG flagged that a key swing factor for Alcon is whether ophthalmic markets improve in FY26, which points to some reliance on broader industry conditions rather than company execution alone.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!ASX:ALC 1-Year Stock Price Chart

See how Alcidion Group's fair value stacks up across multiple valuation models — not just analyst targets.

How This Changes the Fair Value For Alcidion Group

Fair value estimate is A$0.14, unchanged, with the updated estimate remaining at A$0.14. Revenue growth assumption is 4.35%, compared with the previous 4.33%. Net profit margin assumption is 6.15%, compared with the previous 6.19%. Future P/E assumption is 70.62x, compared with the previous 70.60x. Discount rate is 7.87%, compared with the previous 8.06%.

Story Continues

Never Miss an Update: Follow The Narrative

Narratives link a company’s business story to a financial forecast and fair value, so you can see how contracts, guidance and risks fit together. They update over time as new data, guidance and commentary come through.

Head over to the Simply Wall St Community and follow the Narrative on Alcidion Group to stay up to date on:

How growth in annual recurring revenue from multi year modular contracts links to revenue visibility and earnings mix. Why validation of the Miya Precision platform, particularly in the UK and new regions like Canada and the Middle East, matters for international diversification. Key risks around UK revenue concentration, large contract renewals, and higher operating costs from international expansion and regulatory requirements.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ALC.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments